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Background: We previously identiﬁed tumor-reactive lymphocytes in the ﬁrst lymph nodes
that drain the primary tumor. In this study, we performed lymphatic mapping to investigate the
possibility of ﬁnding the ﬁrst lymph nodes that drain metastases, and of learning whether these
lymph nodes contained tumor-reactive lymphocytes suitable for adoptive immunotherapy.
Methods: Nineteen patients were studied. The primary tumor site was colorectal cancer in
seven patients, malignant melanoma in four, ovarian cancer and breast cancer in two, and one
each with pancreatic cancer, cholangiocarcinoma, leiomyosarcoma, and squamous cellular
cancer of the tongue. By injection of Patent blue dye or radioactive tracers around the metas-
tases, we identiﬁed draining lymph nodes from liver metastases (n = 9), intra-abdominal local
recurrences (n = 3), and regional lymph node metastases (n = 7). In six patients, a preoper-
ative lymphoscintigraphy was performed.
Results: We located the ﬁrst draining lymph node or nodes from metastases or local recur-
rences; we named them ‘‘metinel nodes.’’ Lymphocytes from the metinel nodes proliferated,
showed clonal expansion, and produced interferon gamma (via in vitro expansions on stimu-
lation with tumor homogenate) and interleukins, all of which demonstrate the characteristics of
tumor-reactive lymphocytes. Eight of the nineteen patients received immunotherapy on the
basis of tumor-reactive T cells derived from the metinel nodes.
Conclusions: We demonstrate that it is possible to locate the ﬁrst lymph nodes draining
subcutaneous, lymphatic, and visceral metastases, the so-called metinel nodes. Metinel node–
derived lymphocytes may be used to treat disseminated solid cancer, and clinical trials should
evaluate the effect of such treatment.
Key Words: Solid tumors—Metastases—Sentinel node—Lymphatic mapping—Immunother-
apy.
The global cancer registry Globocan shows
10.9 million new incident cases and 6.7 million
deaths worldwide due to cancer in 2002.
1 A total of
24.6 million persons are estimated to be alive with
cancer (within 3 years of diagnosis). Leading causes
of death from cancer, in order, are those of the
lung (1.18 million), stomach (700,000), and liver
(598,000). Most of these deaths were caused by
metastatic disease, and they verify the fact that
surgery and oncological therapy do not cure most
patients with disseminated cancer. The incidence of
cancer will continue to increase, especially in
developing countries, largely due to smoking,
infections, and lifestyles resembling those of people
living in industrialized countries.
1,2 Thus, intensiﬁed
efforts are warranted, both to prevent cancer and to
ﬁnd new modalities of treating patients with meta-
static cancer.
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1454Tumor cells spread by lymphogenous and hema-
togenous routes into the systemic circulation to dis-
seminate the disease. The importance of tumor
lymphangiogenesis has lately been proven in studies
where high levels in colorectal cancer specimens of
lymphangiogenic peptides, and vascular endothelial
growth factor (VEGF)-C and/or VEGF-D promote
tumor lymphangiogenesis and metastasis.
3 The senti-
nel node concept implies that the lymphatic drainage
from a primary tumor ﬁrst drains to a certain locore-
gionallymphnodespeciﬁcforeachindividualandthat
its tumor status is representative for the entire lym-
phatic ﬁeld. The concept is established in staging for
breast cancer
4 and malignant melanoma
5 and has also
been evaluated in several other types of malignancies,
such as colon cancer,
6 ovarian cancer,
7 pancreatic
cancer,
8 and urinary bladder cancer.
9 The technique
has been used as a diagnostic tool to improve staging
and to tailor the extent of regional lymph node dis-
sections. Probably most solid tumors disseminate ﬁrst
through the lymphatics and thereafter enter the sys-
temic circulation via lymphovenous shunts present in
the ﬁrst draining lymph nodes.
10–12 Approximately
half of the lymphatic ﬂuid entering a lymph node
continues directly into the systemic circulation; there-
fore, lymphogenic spreading of the tumor cells may be
mandatory for hematogenic dissemination.
3,13
However, to our knowledge, only one study has
previously evaluated lymphatic mapping in metasta-
ses where liver metastases were investigated.
14
Because it has been proven that both metastases and
primary tumors have the capacity to metastasize
15–17
and induce lymphangiogenesis,
18 we assume that
lymphatic drainage from metastases may have an
equal importance in metastases as the sentinel node
concept in many solid primary tumors for correct
staging. We have previously experienced surprises in
lymphatic mapping within patients with colon can-
cer
6 and urinary bladder cancer
9 regarding primary
tumor lymphatic drainage. We believe that a similar
technique may be of use in surgery for liver metas-
tases and other solid metastatic tumors for correct
staging, and thereby for giving the patients the most
appropriate therapy.
We previously showed that a sentinel node derived
from a primary tumor contains speciﬁc tumor-reac-
tive lymphocytes that have immunological reactivity
toward the tumor in patients with colon cancer
19 and
in patients with urinary bladder cancer.
20 Through
the injection of Patent blue dye or radioactive tracer
subserosally during surgery around the colonic tumor
or transurethrally around the urinary bladder tumor,
the sentinel nodes were found. A biopsy was
performed, and the nodes immunological role and
function were studied. After preparation, the lym-
phocytes were identiﬁed, isolated, and proliferated in
vitro by stimulation of interleukins (ILs) and tumor
antigen. Lymphocytes from sentinel nodes prolifer-
ated dose dependently and secreted interferon (IFN)-
c on stimulation with tumor homogenate.
The aim of the present study was to investigate
lymphatic drainage from metastases and identify ﬁrst
draining lymph nodes. We also analyzed tumor-
reactive immunological properties in lymphocytes
derived from these lymph nodes.
MATERIALS AND METHODS
Patients
Nineteen patients (9 men and 10 women, average
age 51.5 years) with metastases from solid tumors
were included in the study. Patient characteristics are
shown in Table 1. The operations were performed
during the period of November 2003 to January 2007.
The study was approved by the local ethical com-
mittee, and each patient provided informed consent.
The lymph nodes that drained metastases were
identiﬁed by injecting approximately 1 mL Patent
blue dye (PB) (Guerbet, Paris) subserosally or sub-
cutaneously in four places around one of the metas-
tasis or in the tissues close to the local recurrences
with a 27-gauge needle. After the injection of PB, the
ﬁrst draining lymph nodes turned blue within 3 to
10 minutes and were regarded as metastases-draining
lymph nodes. In our previous work, a 10-minute
cutoﬀ was suﬃcient to identify sentinel nodes to
primary tumors. We have experienced that during
this period of time the ﬁrst draining lymph nodes turn
blue. Waiting longer means that a second echelon of
draining lymph nodes may be colored blue, which
does not represent the ﬁrst draining lymph nodes. We
arbitrarily applied the same 10-minute limit when
detecting lymph nodes that drain metastases. These
lymph nodes were either immediately removed or
marked with sutures.
The sources of the liver metastases in our study
were from colorectal cancer in ﬁve patients and in one
patient each from ovarian cancer, breast cancer,
cholangiocarcinoma, and leiomyosarcoma. Four pa-
tients had subcutaneous lymph node metastases from
disseminated malignant melanoma, and one patient
each had metastases from ovarian cancer, breast
cancer, and squamous cell carcinoma of the tongue.
Two patients had intra-abdominal local recurrences
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intra-abdominal local recurrence after surgery for
pancreatic cancer.
Because of these liver metastases, ﬁve patients
underwent partial right-sided liver resections (patients
4,5,6,15,and17),andthreepatientsunderwentpartial
left-sided liver resection (patients 2, 18, and 19). The
patient with metastases resulting from ovarian cancer
(patient 7) had several large, bulky, cystic tumors, and
surgeons performed an almost complete right-sided
liver resection. In four cases, surgery was performed
for solitary colorectal liver metastases (patients 2, 4, 5
and6),andintheremainingﬁvecases,tumor-reducing
surgery was performed.
In six cases, a preoperative lymphoscintigraphy
was performed by a subcutaneous injection of 4 · 10
to 15 MBq Tc-nanokolloid radioactive tracer in
quadrants around the metastasis. The lymphoscin-
tigraphies were performed to plan the surgical pro-
cedure by localizing the lymph node or nodes
draining the metastasis. The position of the metas-
tasis-draining lymph node or nodes was marked on
the skin with a felt-tip pen. When the lymphoscin-
tigraphy was not performed on the day of surgery, a
new peritumoral injection of radioactive tracer was
made at start of surgery. The draining nodes were
intraoperatively identiﬁed by the use of a handheld
gamma detection tube. In four of six cases, a simul-
taneous intraoperative injection of PB was per-
formed.
Preparation of Specimens
Lymph nodes draining metastases and nondraining
lymph nodes (for analytical purposes) were surgically
removed and immediately taken to the laboratory on
ice. In addition, one 5-mm slice of the whole metas-
tasis (including the invasive margin) was also dis-
sected and sent for analysis. Frequently, most of the
lymph node or nodes were used for the expansion
procedure. The remaining specimens underwent
routine histopathological examinations with hema-
toxylin and eosin staining. At the laboratory, slices
<1 mm were cut from the central and peripheral part
of the lymph nodes for analysis by ﬂow cytometry
(FACS) and proliferation analyses. The metastasis
was also analyzed by FACS, and a preparation of the
whole tumor (homogenate) was used.
TABLE 1. Patient characteristics
a
Patient Age (y) Sex
Primary
tumor
Origin
metinel node Tracer
Number
of metinel
nodes
Metinel
node pos/neg
for metastases
Successful
expansion Alive
Follow-up
time (mo)
1 48 M Colon Intra-abdominal
local recurrence
PB 3 3 neg Yes Yes 38
2 54 M Rectum Liver metastasis PB 2 2 neg Yes Yes 38
3 50 M Mal melanoma Subcutaneous
metastasis
PB 2 2 pos No No –
4 77 F Colon Liver metastasis PB 3 3 neg No No –
5 74 M Colon Liver metastasis PB 2 1 pos Yes No –
1 neg
6 66 M Colon Liver metastasis PB 1 MI No Yes 29
7 51 F Ovarian cancer Liver metastasis PB 2 1 pos Yes
b No –
1 neg
8 64 F Ovarian cancer Groin lymph node PB/RT 5 5 pos No No –
9 59 F Pancreatic cancer Intra-abdominal
local recurrence
PB 4 MI No No –
10 39 F Mal melanoma Groin lymph node PB/RT 4 2 neg No Yes 11
11 47 M Mal melanoma Truncal metastasis RT 1 2 pos No No –
12 45 F Breast cancer Cervical lymph node PB/RT 2 2 neg Yes Yes 5
13 33 F Tongue cancer Truncal lymph node RT 3 MI No Yes 6
14 64 F Colon Intra-abdominal
local recurrence
PB 2 1 pos Yes Yes 4
1 neg
15 41 F Breast cancer Liver metastasis PB 2 2 neg No Yes 4
16 39 M Mal melanoma Cervical lymph node PB/RT 2 2 neg No Yes 2
17 20 M Cholangiocarcinoma Liver metastasis PB 3 3 neg Yes No –
18 65 M Colon Liver metastasis PB 3 1 pos Yes Yes 1
2 neg
19 42 F Leiomyosarcoma Liver metastasis PB 4 4 pos Yes Yes 1
pos, positive; neg, negative; Mal, malignant; PB, Patent blue dye; MI, missing information; RT, radioactive tracer (4 · 10–15 MBq
Tc-nanokolloid).
a Data regarding the expansions for patients 1, 2, 5, and 6 also exist in unpublished data.
b Patient died on the projected day of transfusion.
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Single cell suspensions were made from the lymph
nodes and metastases by gentle pressure with a loose-
ﬁtting glass homogenizer as previously described.
19
Brieﬂy, 1 · 10
6 cells were washed in phosphate-buf-
fered saline containing 2% fetal calf serum and .05%
NaN3, then stained with ﬂuorophore conjugated
antibodies toward the cell surface markers CD4,
CD8, CD19, and CD56 (Becton Dickinson). There-
after the cells were investigated with a FACSCalibur
(Becton Dickinson).
For cell cultures, single cell suspensions of metas-
tasis-draining lymph node–derived cells were resus-
pended in RPMI 1640 proliferation media containing
10% human AB serum (Sigma), 1% penicillin-strep-
tomycin (Sigma), and 1% glutamine (Sigma). For
preparation of the antigen source, the metastasis was
homogenized by an Ultra-turrax homogenizer in 5
volumes (w/v) of 2 · phosphate-buffered saline,
followed by 5 minutes denaturation at 95 C. This
tumor homogenate was then used for in vitro acti-
vation and clonal expansion of lymphocytes. The
metastasis-draining lymph node–derived lymphocytes
were finally dispersed into cell culture flasks, at
2 · 10
6 cells/mL of proliferation media, supple-
mented with 100 IU of IL-2 (Proleukin, Chiron) per
milliliter of culture every 3 to 4 days. Tumor
homogenate was diluted to 1:10 and 1:100 and added
to the cell cultures after 3 to 4 days. After 1 to
3 weeks, the cell cultures were restimulated by irra-
diated peripheral blood mononuclear cells from the
patient. These cells were collected by Ficoll-Hypaque
centrifugation
19 and used as antigen-presenting cells
for restimulation together with further addition of
tumor homogenate. To verify clonal expansion of T
lymphocytes, Vb repertoire analyses were performed
in a few cases. To test for functionality, single cell
suspensions were investigated for Th1 and Th2
cytokine production, IFN-c, and IL-4.
After an average period of 4 weeks, expanded cells
were counted, evaluated by FACS, and investigated
for the exclusion of malignant cells and bacteria be-
fore they were considered ready for transfusion. Cells
were washed three times in .9% saline solution
(Natriumklorid Baxter Viaﬂo 9 mg/mL, Baxter)
containing 2% human serum albumin (Baxter) and
prepared in a sterile erythrocyte transfusion bag at
4 · 10
6 cells/mL.
The transfusions took place at the surgical ward as
an intravenous transfusion over the course of 1 hour.
Our criterion for adoptive transfer is a transfusion of
lymphocytes to a patient, regardless of the number of
transferred cells. In our previous studies (M.K.,
unpublished data) of adoptive transfer originating
from sentinel nodes, on average, 71 million clonally
expanded autologous tumor-reactive lymphocytes
were transfused to each patient, and in that pilot
study, the disease of all 16 patients responded to
therapy. We do not know the optimal number of cells
to be transfused for the best or maximum immune
response, but according to our experience, 39.5 mil-
lion transfused cells (the average number of trans-
fused cells in the metinel node study) may be
suﬃcient. The explanation may be that the CD4 cells
proliferate and promote division of eﬀector T cells
and memory T cells when they are stimulated by their
antigen (which is derived from the tumor). The cell
expansion continues in the patient.
RESULTS
Metinel Nodes
Lymph nodes draining liver metastases, intra-
abdominal recurrences, and subcutaneous metastases
were identiﬁed in all 19 cases, with an average num-
ber of 2.6 nodes found per patient (range, 1–5)
(Table 1). We denoted these metastasis-draining
lymph nodes metinel nodes. Seventeen (40%) of the
analyzed metinel nodes were positive for metastatic
disease. In 4 (25%) of 16 patients where data were
available, all metinel nodes were positive for meta-
static disease (range, 2–5), and in 8 (50%) of 16
patients, all metinel nodes (range, 2–3) were negative
for metastatic disease.
Tracer was injected around liver metastases
(n = 9), intra-abdominal recurrences (n = 3), or
close to subcutaneous metastases (n = 7). Draining
metinel nodes appeared visually blue (Fig. 1A) within
3 to 10 minutes after the injection of PB or were
found to be disease positive by lymphoscintigraphy
(Fig. 1B). No complications due to the lymph node
mapping procedure were observed. The method
seems valid for detecting the draining metinel node
regardless of tumor type because the following were
identiﬁed by this method: colorectal cancer (n = 7),
malignant melanoma (n = 4), ovarian cancer
(n = 2), breast cancer (n = 2), pancreatic cancer
(n = 1), squamous cell cancer (n = 1), cholangio-
carcinoma (n = 1), and leiomyosarcoma (n = 1).
Thus, we conclude that lymph nodes draining liver
metastases or local recurrences can readily be iden-
tiﬁed by this simple, safe, and quick procedure.
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nodes draining the area of the metastases were found
within the liver hilum or hepatoduodenal ligament.
The average number of metinel nodes from liver
metastases were 2.4, and 7 (32%) of 22 of the
analyzed metinel nodes were positive for metastatic
disease. Two patients underwent surgery to treat
intra-abdominal local recurrences from colon cancer
(patients 1 and 14); resections of the recurrence and
reresection of the bowel en bloc were performed.
One patient with pancreatic cancer (patient 9)
underwent tumor-reducing surgery to treat a local
intra-abdominal recurrence after a previous Whipple
operation.
Four patients underwent surgery, with lymph node
biopsies performed, to treat subcutaneous metastases
from disseminated malignant melanoma (patients 3,
10, 11, and 16), and one patient each underwent
surgery to treat subcutaneous metastases from dis-
seminated breast cancer (patient 12), groin lymph
node metastasis due to ovarian cancer (patient 8),
and subcutaneous metastases related to squamous
cellular carcinoma of the tongue (patient 13)
(Table 1).
Immunology
We previously demonstrated the presence of
tumor-reactive T lymphocytes in primary tumor-
draining sentinel nodes from patients with colon
19
and urinary bladder cancers.
20 Here, we investigated
whether signs of immune recognition also occurred in
metinel nodes draining metastases. Single cell sus-
pensions were collected from identiﬁed metinel nodes
and investigated by ﬂow cytometry for the presence
of CD4
+, CD8
+ T lymphocytes, CD19
+ B lym-
phocytes, and CD56
+ natural killer (NK) cells
(Table 2). Most of the metinel nodes were predomi-
nated by CD4
+ T helper cells, with an average
CD4
+/CD8
+ ratio of 2.3 (range, .1–6.6). However,
five patients (patients 3, 6, 11, 12, and 19) displayed
an increase in the fraction of CD8
+ cytotoxic T cells.
Two of these patients had malignant melanoma. The
metinel nodes contained an average of 9.5% (range,
.1–55) CD19
+ B lymphocytes and an average of
2.1% (range, 0–18.9) CD56
+ NK cells.
CD4
+ cells are crucial for initializing both the
cellular and humoral immune response toward, for
example, tumors. CD4
+ cells recognize antigens ex-
pressed on major histocompatibility complex II and
have the capacity to catalyze the immune response in
B cells, Antigen presenting cells (APCs), and CD8
+
cells. CD4
+ cells have, compared with CD8
+ cells, a
long-term capacity of acting both as effector T cells
and as memory cells. CD8
+ cells are mainly effector
cells and will act during a few weeks, but further
recruitment of CD
+8 cells is maintained by CD4
+
cells. The expansion procedure aims to increase the
number of CD4
+ cells, and the CD4
+/CD8
+ ratio
can be regarded as a measurement of how well this
can be achieved. The average ratio of CD4
+/CD8
+
cells at the start of the procedure was 2.6 for patients
who underwent successful expansions and 2.1 for
patients who underwent unsuccessful expansions.
Consequently, the CD4
+/CD8
+ ratios were 24%
higher for patients with successful expansions.
To test for recognition of tumor antigen, the
number of metinel node–acquired lymphocytes from
nine patients (patients 1, 2, 5, 7, 12, 14, 17, 18, and
19) were increased successfully by the addition of low
FIG. 1. (A) After intraoperative injection of Patent blue dye
around liver metastasis in patient 18, the metinel node in the
hepatoduodenal ligament is blue. (B) Preoperative percutaneous
injection of 4 · 15 MBq Tc-nanokolloid around ovarian cancer
groin local recurrence (patient 8) demonstrates a medially and
distally situated metinel node after 10 minutes.
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97 · 10
6 cells (range, 5–285 · 10
6) were collected,
and the cells were expanded on average for 32 days
before transfusion. At the time of transfusion, a mean
of 39.5 · 10
6 tumor-reactive T cells (range, .7–
170 · 10
6) were returned (Table 2). In patient 7, cells
were expanded and prepared for transfusion, but the
patient suddenly died without receiving any cells. No
side effects from transfusion of expanded T lym-
phocytes were seen, and the patients were discharged
from the hospital on the same day of the transfusion.
The expansions were successful in ﬁve of seven pa-
tients who had colorectal primary tumor; one of two
in patients with ovarian cancer and breast cancer;
and one patient each with cholangiocarcinoma and
leiomyosarcoma. The following expansions failed in
all patients: malignant melanoma (n = 4), pancreatic
cancer (n = 1), and squamous cellular cancer
(n = 1). An analysis of the CD4 Vb repertoire from
patient 11 was investigated by ﬂow cytometry of
metinel node–acquired lymphocytes (Fig. 2) and
revealed an increase and clonal expansion of Vb
families 7.1, 13.2, and 20. In addition, analysis of the
Vb repertoire in two independently cultured metinel
nodes derived from one breast cancer metastasis
(patient 12) (data not shown) demonstrated clonal
expansion after 12 days short-term culture of the
same T cell receptor families in both nodes (Vb 4, Vb
9, Vb 20, and Vb 21.3). We conclude that cultures of
metinel node–acquired lymphocytes expand in the
presence of autologous tumor extract and IL-2.
Cells from patient 8, stimulated at the end of the
expansion, demonstrated a high production of IFN-c
of >1000 pg/mL (Fig. 3) and no detectable IL-4
(data not shown), indicating a Th1 response. In an
additional patient (patient 5), the stimulated IFN-c
secretion was 155 pg/mL while only a low IL-4 pro-
duction of 30 pg/mL was found, again demonstrating
a Th1-predominant response pattern.
TABLE 2. Immunology of single cell suspensions collected from metinel nodes
Patient
Time in
culture (d)
No. of
cells at
start
(millions)
No. of
cells
at end
(millions)
Ratio of
cells
start/end
Start
(% gated),
ratio
CD4/CD8
and
CD19/CD56
End, ratio
CD4/CD8 and
CD19/CD56
Ratio
CD4/CD8
start
Ratio
CD4/CD8
end
1 31 100 80 .8 24/11 and 55/) 24/16 and )/) 1.8 1.5
23 3 4 2 4 0 .95 51/15 and 13/) 24 and .12/) 3.4 1.5
3 28 – – – 8/39 and 1/) –. 2 –
4 20 65.4 – – 37/9 and )/) – 4.1 –
5 43 130 – 1.3 47/7.1 and 28/1.3 73/22 and .09/.17 6.6 3.3
6 6 5 – – .2/1.6 and .4/.4 – .125 –
76 5 . 7 .02 16.4/6.5 and 24.2/1.6 – 2.5 –
8 52 42.6 – – 15.9/7.6 and 9/3.4 – 2.1 –
91 5 1 2 – – – – – –
10 74 166.8 5 .03 40/7 and .5/.3 – 5.7 –
11 35 209 140 9.3 12.8/16.3 and 1.9/0 – .8 –
12 31 285 2 .01 16.4/31.8 and .1/0 – .5 –
13 24 3 – – – – – –
14 32 30 1 .05 – – – –
15 48 36 – – 0/.1 and 0/0 – 0 –
16 45 20 – – 28.25/6.95 and 1.15/0 – 4.1 –
17 20 89 4 .04 5.8/2.6 and 4.2/.2 34.2/30.4 and 7.6/20.1 2.2 1.1
18 29 67 4 .06 9.7/3.8 and 1.3/.1 – 2.6 –
19 43 11 15 1.36 12.7/15.8 and 3/18.9 85/3 and .9/8.4 .8 28.3
FIG. 2. In patient 13, the T cell receptor Vb repertoire was
investigated by ﬂow cytometry in two sentinel (nodes at the day of
operation and after in vitro cell culture (43 days). Clonal expansion
of Vb families 7.1, 13.2, and 20 were detected in the CD4
+ T cell
population.
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we found that some T cells expressed Fox P3, indi-
cating that these cells in fact were T regulatory cells.
DISCUSSION
We show that it is possible to ﬁnd the ﬁrst lymph
nodes draining various types of metastases by lym-
phatic mapping by means of dye or radioactive
tracers. We have named these metastasis-draining
lymph nodes ‘‘metinel nodes’’ to show both the
analogy and diﬀerence to the well-known term
‘‘sentinel node,’’ which means the ﬁrst node to receive
lymphatic drainage from a primary tumor. In 19
studied cases, we demonstrated three diﬀerent ways
of identifying these nodes by injection of tracers
subserosally around liver or intra-abdominal metas-
tases, close to subcutaneous metastases, or into local
lymph node metastases.
The fact that it is possible to expand the metinel
node–derived lymphocytes via in vitro expansions
during several weeks of time, together with our
analysis that they contain lymphocytes that show
clonal expansion toward tumor antigens and produce
high levels of IFN-c in the expansions, are evidence
that they contain tumor-reactive lymphocytes. These
cells are mainly T-helper 1 cells that have developed
an immunological response toward the metastatic
cells. We suggest that these T cells may be used in
future trials of adoptive cellular therapy of dissemi-
nated solid cancer.
Studies have demonstrated that tumor growth be-
yond a certain size required angiogenesis
21 and that
the amount of neovascularization peritumorally was
a predictor of metastatic disease.
22 Far less is known
about the speciﬁc factors regulating the lymphan-
giogenesis around a tumor and its possible impor-
tance, much as a result of the difﬁculty of
discriminating between lymphatics and blood vessels.
However, during recent years, the molecular path-
ways signaling for lymphangiogenesis have been de-
scribed, and these studies have revealed that
lymphangiogenesis is a major component of the
metastatic process.
The lymphatic capillaries consist of thin-walled,
low-pressure vessels that drain the interstitium. When
the surrounding interstitial ﬂuid pressure increases,
the walls of the lymphatics are stretched and open to
passage of cells or ﬂuids. The lymphatic capillaries
are joined into major lymphatic collecting vessels and
ﬁltered through at least one lymph node before
entering the venous circulation.
23 After entering the
node, approximately half of the lymphatic ﬂuid
continues directly into the blood before the rest
drains into an efferent lymphatic vessel.
24
A malignant tumor causes a peritumoral increase
of lymphatic vessels mediated through VEGF. Stud-
ies have shown that high levels of the cytokine cas-
cade of VEGF-C and VEGF-D promote the tumoral
lymphangiogenesis and that inhibition of their joint
receptor, VEGFR-3, suppresses the eﬀects. Kawa-
kami et al.
25 showed that high levels of VEGF-C and
its receptor, VEGFR-3, correlated with increased
lymph node metastases and lymphatic invasion in
human colorectal cancer. White et al.
26 concluded
that patients operated on for colon cancer had an
overexpression of VEGF-D, but not of its receptor
VEGFR-3, which correlated with a decrease in dis-
ease-free interval and overall survival. A study based
on 110 patients with breast cancer showed that lymph
vessels were present more often in metastatic axillary
lymph nodes (85%) than in nonmetastatic lymph
nodes (25%),
18 and that intranodal and perinodal
lymphatic endothelial cell proliferation fractions were
higher in metastatically involved lymph nodes. Taken
together, all these ﬁndings support lymphangiogene-
sis in metastases.
Thus, a tumor causes an upregulation of lymph-
angiogenic factors that leads to an increase in perit-
umoral lymphatic vessels in both tumors and
metastases. It is likely that these newly developed
FIG. 3. Amount of interferon gamma secreted into the superna-
tant measured by enzyme-linked immunosorbent assay. Data pre-
sented are for patient 7 after 35 days of in vitro cell culture.
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vessels and lymph nodes. Shed tumor cells may in-
vade these newly formed vessels, and the dissemina-
tion of tumor cells is facilitated. The present study
shows that this process can be visualized by lym-
phatic mapping, and the ﬁrst draining lymph node
from the metastasis, the metinel node, may be iden-
tiﬁed.
Animal studies showed that metastases had the
capacity to metastasize. Mice inoculated with pul-
monary venous blood from mice having pulmonary
metastases developed disseminated cancer disease
after injection into the tail vein, showing that pul-
monary metastases shed viable circulating cells.
16
Similarly, Hoover and Ketcham
15 demonstrated that
mice who had undergone amputation of their pri-
mary tumors and now only had pulmonary metas-
tases experienced spread of the tumor cells speciﬁcally
into the lungs after parabiosis.
In surgery for colorectal liver metastases, it is not
standard to perform a biopsy of perihepatic lymph
nodes. Nakamura et al.
27 reported a 4-year survival
of 40% in node-positive patients, but the study co-
hort was small. Most studies identify few 5-year
survivors after liver resection for colorectal liver
metastases involving positive perihepatic lymph
nodes.
28 These lymph node metastases are unlikely to
be of lymphatic origin from the primary colonic
tumor; instead, they may be explained by hematog-
enous spread to the liver followed by lymphogenic
spreading from the liver metastases to the perihepatic
lymph nodes.
29 Correct perihepatic lymphatic staging
is beyond dispute, not only because the increased
morbidity in patients having perihepatic lymph node
metastases, but also because of the improvements in
systemic therapies. In the nine cases of resected liver
metastases in our study, all metinel nodes were found
among perihepatic nodes within the hepatoduodenal
ligament or liver hilum. Most of the liver is drained
by deep hepatic lymphatics, the upper inner part of
the liver drains to nodes around the end of inferior
caval vein, and the lower inner part drains to hepatic
nodes through the liver hilum.
30 The superﬁcial part
of the liver lymphatic drainage is divided into two
main directions; the posterior surface drains into
pericaval nodes, and the inferior, anterior, and
superior surface drains into hepatic nodes through
the liver hilum. In all cases of resected liver metas-
tases, the injections of PB were performed subsero-
sally on the inferior, anterior, or superior surface of
the liver. Our identiﬁed perihepatic metinel nodes
were located corresponding to the superﬁcial lym-
phatic drainage of the liver.
Despite the prognostic importance of these peri-
hepatic lymph nodes, we have only found one article
in the literature describing lymphatic mapping origi-
nating from liver metastases. Kane et al.
14 demon-
strated in a study of 11 patients with colorectal liver
metastases that it was possible to perform lymphatic
mapping by the intraoperative injection of isosulfan
blue dye in a peritumoral and subcapsular manner.
The basic premise was that the occurrence of extra-
hepatic metastases within the normal lymphatic
drainage of the liver was considered to be remetas-
tases from the colorectal metastases. They found
blue-colored nodes in seven patients (54%), all within
the liver hilum, falciform ligament, or gallbladder
fossa. In three of these patients, the nodes were not
detected by the surgeon before the mapping proce-
dure. Like our results, they concluded that hepatic
lymphatic mapping was safe, rapid, and simple
technique to perform in humans.
The importance of lymphatic mapping in liver
surgery for metastases was underlined by Grobmyer
et al.,
31 who concluded that routine lymph node
sampling had a low yield in patients without sus-
pected perihepatic disease by computed tomographic
scan or positron emission tomography, or at surgical
exploration. Further, another study demonstrated
that microscopic perihepatic positive lymph node
disease is associated with the same poor prognosis as
in macroscopic positive disease and suggests, there-
fore, that lymph node dissection should be system-
atic.
32
Lymphoscintigraphy has been used to ﬁnd sentinel
nodes from primary tumors,
33 but to our knowledge,
it has not been reported as a tool to locate lymph
nodes draining subcutaneous metastases. The radio-
active tracer facilitated the intraoperative identiﬁca-
tion of the metinel nodes by a gamma probe used as a
complement to PB. In those cases, the lymphoscin-
tigraphy was made days before surgery, and new
injections of radioactive tracers were provided on the
day of surgery. One to three metinel nodes were de-
tected in our six patients.
In the late 1950s, the immunosurveillance hypoth-
esis was introduced
34 supporting the fact that tumor
cells possessed new antigenic potentials and provoked
an immunological reaction that could eradicate a
tumor completely. In the last decade, the hypothesis
has been proven in mice and humans. The role of the
immune system in cancer diseases is demonstrated by
immunodeﬁcient patients having both an overrepre-
sentation of virus-induced malignancies and an in-
creased probability of developing cancer of nonviral
cause. Cardiac transplant recipients have, for exam-
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of lung tumors than the general population.
35 Much
data also supports the fact that both the cellular and
the humoral immune systems develop immune re-
sponses against tumors. Bevacizumab, a monoclonal
antibody against VEGF, functions as an inhibitor of
angiogenesis, inhibits growth of human tumor cells in
mice, and prolongs the overall median survival in
human metastatic colorectal cancer.
36 The presence
of tumor-reactive lymphocytes in sentinel nodes
19,20
is an example of the function of the cellular immune
system and a positive prognostic factor for survival in
colorectal and ovarian cancer.
37–39
In our earlier study, we made a single cell suspen-
sion of the lymphocytes from sentinel nodes. They
were expanded in vitro, stimulated by tumor
homogenate, IL-2, and antigen-presenting cells. In
the present expansions, we proved it was possible to
ﬁnd tumor-reactive lymphocytes in metinel nodes and
to perform adoptive immunotherapy based on them.
The preliminary results seems promising, with total
or partial regression of some liver and lung metas-
tases (M.K., unpublished data). In this study, the
expansions were performed in exactly the same way
as in our previous studies, except that the source of
the lymphocytes was derived from lymph nodes
draining metastases—that is, metinel nodes. The fact
that we succeeded in nine cases in proliferating the
lymphocytes via in vitro expansions over more than a
month is evidence for the presence of tumor-reactive
lymphocytes. Because the expansions were continu-
ously stimulated with autologous tumor homogenate
and antigen-presenting cells together with IL, only
lymphocytes that were a priori stimulated by antigens
derived from the tumor could proliferate and survive
for such a long time. Figure 2 demonstrates the Vb
repertoire in CD4-positive cells in two metinel nodes
in patient 11, thus showing which types of T-helper
cell receptors were found at the end of expansion. The
ﬁgure shows clonal expansion of Vb 7.1, 13.2, and 20,
demonstrating the presence of tumor-reactive lym-
phocytes toward three different types of tumor anti-
gens.
These collective facts point out the presence of
tumor-reactive type 1 T-helper lymphocytes in meti-
nel nodes. T helper lymphocytes play a central role in
initiating the adoptive immune defense. In 9 of 19
patients, the cells survived until the time for trans-
fusion, and 8 patients underwent intravenous adop-
tive autologous T cell transfusion. Approximately
half of all patients who underwent the expansion
procedure died as a result of a combination of too
few cells at the start and the initial presence of
immunosuppressive factors that not could be over-
come. Six of eight patients who received transfusions
are still alive, although the follow-up time varies
(Table 1). Our results are encouraging because the
prognosis in these type of cases is usually poor.
In this study, we have shown that it is possible to
ﬁnd the draining lymph nodes from diﬀerent types of
metastases. We named these nodes ‘‘metinel nodes,’’
and they contain tumor-reactive lymphocytes, pref-
erentially T-helper cells with Th1 response. We have
also demonstrated that it is possible to proliferate
these cells in vitro and, if the expansion procedure is
successful, to use the cells for adoptive immunother-
apy.
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